Stephen van Helden

Partner, Planetary Health Investments, Novo Holdings US

📍 United States🔄 Updated September 2026💼 5 investments📅 4 years investing🗓 Last invested Sep 2023
Angel investor🌍 United States
5
Total investments
1
Early stage
0
Mid stage
3
Late stage
4y
Years active

Portfolio

4 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Sep 2023
Elo Life Systems is reimagining the future of food – focusing on ingredients that empower consumers to feel good about the food they eat every day. From unique plant-based sweeteners to saving crops like the banana from extinction, Elo harnesses the untapped potential of nature to make food tastier, healthier and resilient while requiring less from the planet.
Board Member
Feb 2023
Aquafortus Technologies Limited is a company at the cutting edge of water technology. Aquafortus has developed a novel non-thermal liquid to liquid crystallizer (the ABXTM), that reduces wastewater brine to dry salt and clean water. Zero Liquid Discharge (ZLD) means that practically all the water is recovered from the wastewater and that the remaining waste can be shovelled onto a truck for final disposal. The ZLD market has grown rapidly due to government regulations globally that compelled heavily polluting and water-intensive industries to go ZLD or face massive fines and ultimately be shut down. Aquafortus’ ABXTM system is a novel liquid-to-liquid crystallizer that promotes the formation of salt crystals via a proprietary direct contact crystallization process using Aquafortus’ patented solutions, which are called the Aquafortus Absorbent and the Aquafortus Regenerant. The ABXTM system efficiently reduces highly concentrated brines to dry salt and produces clean water. The Aquafortus Absorbent can precipitate all salts commonly found in industrial wastewaters, including troublesome salts like lithium chloride. The Aquafortus ABXTM system is the only known continuous and regenerable process that can wholly replace energy intensive Thermal Crystallizers in a ZLD treatment train.
Board Member
Jan 2023
Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster. We are targeting the growing need for throughput with robust solutions for clinical and large-scale proteomics, and we have a very ambitious business plan to bring the community closer to the clinic. We are basing our design on years of experience with nano-UHPLC R&D and application support, critically rethinking the necessary system architectures for successful sample separation before mass spectrometric analysis.
Board Member
Dec 2022
We’re on a journey to Grow the Future of Materials. How? By unlocking the unique properties of mycelium, the root structure of mushrooms. Our patented technology, Fine Mycelium™, unleashes a new class of materials crafted from nature, engineered for performance, and built for a resilient future. Our impact on future generations steers our innovations today. From our expertise in mycology and materials science to our manufacturing innovations, we’re creating new possibilities for industry. We’re an outstanding team of scientists, engineers, product experts, artists, leaders—and you.
Experience · 8 entries
All (8)
Investments (5)
Board (5)
2023
Board Member
Sep 2023
Elo Life Systems is reimagining the future of food – focusing on ingredients that empower consumers to feel good about the food they eat every day. From unique plant-based sweeteners to saving crops like the banana from extinction, Elo harnesses the untapped potential of nature to make food tastier, healthier and resilient while requiring less from the planet.
Board Member
Feb 2023
Aquafortus Technologies Limited is a company at the cutting edge of water technology. Aquafortus has developed a novel non-thermal liquid to liquid crystallizer (the ABXTM), that reduces wastewater brine to dry salt and clean water. Zero Liquid Discharge (ZLD) means that practically all the water is recovered from the wastewater and that the remaining waste can be shovelled onto a truck for final disposal. The ZLD market has grown rapidly due to government regulations globally that compelled heavily polluting and water-intensive industries to go ZLD or face massive fines and ultimately be shut down. Aquafortus’ ABXTM system is a novel liquid-to-liquid crystallizer that promotes the formation of salt crystals via a proprietary direct contact crystallization process using Aquafortus’ patented solutions, which are called the Aquafortus Absorbent and the Aquafortus Regenerant. The ABXTM system efficiently reduces highly concentrated brines to dry salt and produces clean water. The Aquafortus Absorbent can precipitate all salts commonly found in industrial wastewaters, including troublesome salts like lithium chloride. The Aquafortus ABXTM system is the only known continuous and regenerable process that can wholly replace energy intensive Thermal Crystallizers in a ZLD treatment train.
Board Observer
Feb 2023
We are accelerating the worlds transformation to sustainable materials, by replacing fossil fuel sources with plants. We believe that all products should be responsibly sourced, traceable, and transparent — the sustainable source™. At geno, we are breaking the planets reliance on these fossil fuels by creating something better. Our vision to drive climate action at scale starts by making the same molecules, ingredients, and materials we rely on every day, but deriving them from more sustainable sources. Spanning products across a wide variety of industries, geno’s technologies power high-performance at leading scale and volume, delivering plant-derived ingredients to some of the world’s largest brands. And with that we are shaping the creation of more transparent, traceable, and responsible global supply chains for brands and their consumers to rely on. Our technology and capabilities, developed and honed over two decades, harness the ever-increasing power of biotechnology, where microorganisms and industrial processes are designed to ferment plant sugars into materials and ingredients. geno Innovation Center is home to our world-class research and development team of engineers and scientists who have deployed more than $300 million in technology investment, collaborating to create a portfolio of 2,200 patents and applications. The IP covers product pathways, synthetic biology approaches to engineering microorganisms, processes to bio-manufacture products, their sometimes unique biological compositions, and product applications. We work closely with some of the world’s leading brands to develop solutions that align superior performance and economics with sustainability. We also produce and market our own branded products and license our geno technology to some of the world’s largest manufacturers including Novamont, Qore® (a joint venture of Cargill and HELM), Covestro, and Aquafil. Feeling like you’d be a fit? Join us: http://www.genomatica.com/careers/
Board Member
Jan 2023
Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster. We are targeting the growing need for throughput with robust solutions for clinical and large-scale proteomics, and we have a very ambitious business plan to bring the community closer to the clinic. We are basing our design on years of experience with nano-UHPLC R&D and application support, critically rethinking the necessary system architectures for successful sample separation before mass spectrometric analysis.
2022
Board Member
Dec 2022
We’re on a journey to Grow the Future of Materials. How? By unlocking the unique properties of mycelium, the root structure of mushrooms. Our patented technology, Fine Mycelium™, unleashes a new class of materials crafted from nature, engineered for performance, and built for a resilient future. Our impact on future generations steers our innovations today. From our expertise in mycology and materials science to our manufacturing innovations, we’re creating new possibilities for industry. We’re an outstanding team of scientists, engineers, product experts, artists, leaders—and you.
Show all 8 entries ↓
Investment activity
2022–2023 · 5 investments
2022120234
Recent (last 2 years)Earlier